DQP-26

N/A

Report date: 2023/08/25 16:57:10
NME

Base Information

Drug NameDQP-26
Drug Alias NameDQP-26
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptor ionotropic, NMDA 2C modulatorsGlutamate receptor ionotropic, NMDA 2D modulators
TargetsGlutamate receptor ionotropic, NMDA 2CGlutamate receptor ionotropic, NMDA 2D
Therapy Area/IndicationsNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEmory UniversityJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesEmory UniversityJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsNervous System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A